PTC Therapeutics (PTCT) Stock Price, News & Analysis

Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Key Stats

• Today's Range: $38.94 to $42.74
• 50-Day Range: $31.42 to $44.87
• 52-Week Range: $19.75 to $46.98
• Volume: 1.04 million shs
• Average Volume: 738,844 shs
• Market Capitalization: $3.03 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.31
• Consensus Rating: Hold

PTC Therapeutics Stock Analysis - MarketRank™

PTC Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 556th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

PTC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 6 buy ratings, 5 hold ratings, and 3 sell ratings.

Amount of Analyst Coverage

PTC Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PTC Therapeutics are expected to grow in the coming year, from ($4.88) to ($4.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PTC Therapeutics is -6.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PTC Therapeutics is -6.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.34% of the outstanding shares of PTC Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

PTC Therapeutics has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in PTC Therapeutics has recently increased by 4.94%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PTC Therapeutics does not currently pay a dividend.

Dividend Growth

PTC Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.38

Percentage of Shares Shorted

6.34% of the outstanding shares of PTC Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

PTC Therapeutics has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in PTC Therapeutics has recently increased by 4.94%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.57

News Sentiment

PTC Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for PTC Therapeutics this week, compared to 5 articles on an average week.

MarketBeat Follows

3 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PTC Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.50% of the stock of PTC Therapeutics is held by insiders.

PTCT Stock Analysis - Frequently Asked Questions

How have PTCT shares performed this year?

PTC Therapeutics' stock was trading at $27.56 at the beginning of the year. Since then, PTCT stock has increased by 42.3% and is now trading at $39.23.
View the best growth stocks for 2024 here.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its quarterly earnings results on Thursday, October, 26th. The biopharmaceutical company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by $0.91. PTC Therapeutics's revenue for the quarter was down 9.4% on a year-over-year basis.

Who are PTC Therapeutics' major shareholders?

Top institutional investors of PTC Therapeutics include Wellington Management Group LLP (10.23%), State Street Corp (3.76%), Janus Henderson Group PLC (2.43%) and Geode Capital Management LLC (2.33%). Insiders that own company stock include Matthew B Klein, Stuart Walter Peltz, Michael Schmertzler, Mark Elliott Boulding, Eric Pauwels, Neil Gregory Almstead, Lee Scott Golden, Pierre Gravier, Emily Luisa Hill, Christine Marie Utter, Jerome B Zeldis, Allan Steven Jacobson, David P Southwell, Alethia Young, Emma Reeve and Stephanie Okey.
View institutional ownership trends.

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

• Last Earnings: 10/26/2023
• Today: 11/17/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PTCT
• CUSIP: N/A
• CIK: 1070081
• Web: www.ptcbio.com
• Phone: (908) 222-7000
• Fax: 908-222-7231
• Employees: 1,410
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $41.31
• High Stock Price Target: $64.00
• Low Stock Price Target: $26.00
• Potential Upside/Downside: +5.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-626,600,000.00
• Net Margins: -50.32%
• Pretax Margin: -47.24%
• Return on Equity: N/A
• Return on Assets: -16.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.10
• Quick Ratio: 2.17

Sales & Book Value

• Annual Sales: $937.82 million
• Price / Sales: 3.23
• Cash Flow: $2.16 per share
• Price / Cash Flow: 18.17
• Book Value: ($13.67) per share
• Price / Book: -2.87

Miscellaneous

• Outstanding Shares: 77,120,000
• Free Float: 72,883,000
• Market Cap: $3.03 billion
• Optionable: Optionable
• Beta: 0.63